RxDoctor Payments Data

Margaret Zaliponi

Nurse Practitioner · Pittsburgh, PANPI 1851843379

Payments from drug & device makers

$606in general payments, 2019–2025

Across 29 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Averitas Pharma Inc.$264
  • Indivior Inc.$108
  • Protega Pharmaceutials Inc$72
  • Valinor Pharma, LLC$54
  • Braeburn Inc.$52
  • Hikma Pharmaceuticals USA$28
  • plus $27 from 1 others

What the payments were for

  • Food & beverage$57895%
  • Education$285%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Averitas Pharma Inc.14$264
Indivior Inc.5$108
Protega Pharmaceutials Inc3$72
Valinor Pharma, LLC3$54
Braeburn Inc.2$52
Hikma Pharmaceuticals USA1$28
Melinta Therapeutics, LLC1$27

How this compares

$606 in reported general payments places this provider in the 75th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,533
Medicare patients
15
Services billed
17

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen817$17,039
MovantikNaloxegol Oxalate34$13,581
Oxycodone Hcl801$13,570
Buprenorphine55$12,429
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen446$12,088
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl71$10,302
Gabapentin426$5,917
Ibuprofen97$915
Pregabalin36$828
Morphine Sulfate ErMorphine Sulfate20$764
Tizanidine Hcl73$675
Lidocaine11$601
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine14$550
Cyclobenzaprine Hcl126$515
Methocarbamol56$483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Buprenorphine Hcl$28$22,944139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →